Cancer
Cardiff CRDF-004
Colorectal Cancer
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
Contact Research Team:
[email protected]
Site principal investigator:
Marc Roth, MD
Learn more about this study:
NCT06106308